ClinVar Miner

Submissions for variant NM_000528.4(MAN2B1):c.1A>G (p.Met1Val)

gnomAD frequency: 0.00003  dbSNP: rs967834240
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Counsyl RCV000667554 SCV000792026 uncertain significance Deficiency of alpha-mannosidase 2017-06-05 criteria provided, single submitter clinical testing
Illumina Laboratory Services, Illumina RCV000667554 SCV001281509 uncertain significance Deficiency of alpha-mannosidase 2018-01-13 criteria provided, single submitter clinical testing This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease.
Genome-Nilou Lab RCV000667554 SCV002027043 uncertain significance Deficiency of alpha-mannosidase 2021-09-05 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV002469244 SCV002766068 uncertain significance not specified 2022-11-08 criteria provided, single submitter clinical testing Variant summary: MAN2B1 c.1A>G (p.Met1Val) alters the initiation codon and is predicted to result either in absence of the protein or truncation of the encoded protein due to translation initiation at a downstream codon (Met24). The variant allele was found at a frequency of 8.9e-05 in 146180 control chromosomes. This frequency is not significantly higher than expected for a pathogenic variant in MAN2B1 causing Alpha-Mannosidosis (8.9e-05 vs 0.0016), allowing no conclusion about variant significance. To our knowledge, no occurrence of c.1A>G in individuals affected with Alpha-Mannosidosis and no experimental evidence demonstrating its impact on protein function have been reported. Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance.
Invitae RCV000667554 SCV003279549 uncertain significance Deficiency of alpha-mannosidase 2022-10-13 criteria provided, single submitter clinical testing This sequence change affects the initiator methionine of the MAN2B1 mRNA. The next in-frame methionine is located at codon 24. This variant is present in population databases (no rsID available, gnomAD 0.04%). This variant has not been reported in the literature in individuals affected with MAN2B1-related conditions. ClinVar contains an entry for this variant (Variation ID: 552319). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Ambry Genetics RCV002530715 SCV003736966 uncertain significance Inborn genetic diseases 2021-03-26 criteria provided, single submitter clinical testing The c.1A>G (p.M1?) alteration is located in coding exon 1 of the MAN2B1 gene and consists of a A to G substitution at nucleotide position 1. This changes the amino acid from a methionine to a valine (V) at the initiation codon. Sequence variations that modify the initiation codon (ATG) are expected to cause a shift in the mRNA reading frame and are typically deleterious in nature (Richards, 2015). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.
GeneDx RCV003128685 SCV003805891 uncertain significance not provided 2022-08-24 criteria provided, single submitter clinical testing Initiation codon variant in a gene for which loss of function is a known mechanism of disease; Has not been previously published as pathogenic or benign to our knowledge

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.